- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03409744
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
May 1, 2023 updated by: Regeneron Pharmaceuticals
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
The primary objectives of the study are:
- To evaluate the long-term safety and tolerability of evinacumab in patients with Homozygous Familial Hypercholesterolemia (HoFH)
- To evaluate the long-term safety and tolerability of evinacumab in adolescent patients with HoFH
The secondary objectives of the study are:
- To evaluate the effect of evinacumab on lipid parameters in patients with HoFH
- To evaluate the effect of evinacumab on lipid parameters in adolescent patients with HoFH
- To evaluate the potential development of anti-evinacumab antibodies
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
116
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Clinical Trial Site
-
-
Western Australia
-
Perth, Western Australia, Australia, 6000
- Clinical Trial Site
-
-
-
-
-
Innsbruck, Austria, 6020
- Regeneron Study Site
-
-
Wien
-
Vienna, Wien, Austria, 1090
- Regeneron Study Site
-
-
-
-
-
Quebec, Canada, G1V 4W2
- Clinical Trial Site
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 7K9
- Clinical Trial Site
-
-
-
-
Kateřinská
-
Praha 2, Kateřinská, Czechia, 121 08
- Regeneron Study Site
-
-
-
-
Cedex
-
Dijon, Cedex, France, 21079
- Clinical Trial Site
-
-
Cedex 13
-
Paris, Cedex 13, France, 75651
- Clinical Trial Site
-
-
Cedex 5
-
Marseille, Cedex 5, France, 13385
- Clinical Trial Site
-
-
-
-
-
Ioannina, Greece, 45500
- Clinical Trial Site
-
-
Athens
-
Kallithea, Athens, Greece, 17674
- Regeneron Study Site
-
-
-
-
Campania
-
Napoli, Campania, Italy, 80131
- Clinical Trial Site
-
-
Rome
-
Roma, Rome, Italy, 161
- Clinical Trial Site
-
-
-
-
Aichi
-
Obu, Aichi, Japan, 474-8710
- Clinical Trial Site
-
-
Fukuoka
-
Kurume, Fukuoka, Japan, 830-8522
- Regeneron Study Site
-
-
Hyogo
-
Nishinomiya, Hyogo, Japan, 662-0918
- Regeneron Study Site
-
-
Ishikawa
-
Kanazawa, Ishikawa, Japan, 920-8641
- Regeneron Study Site
-
-
Osaka
-
Kita-ku, Osaka, Japan, 530-0001
- Regeneron Study Site
-
Suita, Osaka, Japan, 564-8565
- Regeneron Study Site
-
Suita, Osaka, Japan, 565-0871
- Regeneron Study Site
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Clinical Trial Site
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2000
- Regeneron Study Site
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7925
- Regeneron Study Site
-
-
-
-
-
Ivano-Frankivsk, Ukraine, 76075
- Clinical Trial Site
-
Kharkiv, Ukraine, 61039
- Clinical Trial Site #1
-
Kharkiv, Ukraine, 61176
- Clinical Trial Site #2
-
Kyiv, Ukraine, 02660
- Clinical Trial Site
-
Kyiv, Ukraine, 3680
- Rgeneron Study Site
-
-
-
-
California
-
Los Angeles, California, United States, 90048
- Clinical Trial Site
-
-
Florida
-
Boca Raton, Florida, United States, 33434
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Clinical Trial Site
-
-
New York
-
New York, New York, United States, 10029
- Clinical Trial Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45227
- Clinical Trial Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Clinical Trial Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, United States, 75226
- Clinical Trial Site
-
Dallas, Texas, United States, 75390
- Clinical Trial Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Completion of the parent study in which they participated
- Able to understand and complete study-related questionnaires
Key Exclusion Criteria:
- Significant protocol deviation in the parent study based on the investigator's judgment, such as non-compliance by the patient
- Concomitant medications that have not been stable prior to the baseline visit
- Adverse event leading to permanent discontinuation from parent study
- Any new condition or worsening of an existing condition, which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study
- Member of the clinical site study team and/or his/her immediate family
- Pregnant or breastfeeding women
- Women of childbearing potential who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 24 weeks after the last dose of study drug
- Men who are sexually active with women of childbearing potential and are unwilling to use the following forms of medically acceptable birth control during the study drug treatment period and for 24 weeks after the last injection of study drug: vasectomy with medical assessment of surgical success OR consistent use of a condom.
Note: Other protocol defined Inclusion/Exclusion criteria apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: evinacumab
|
Intravenous (IV) administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change in Low-Density Lipoprotein Cholesterol (LDL-C) over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Absolute change in LDL-C over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Percent change in Apolipoprotein B (Apo B) over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Absolute change in Apo B over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Percent change in non-High-Density Lipoprotein Cholesterol (HDL-C) over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Absolute change in non-HDL-C over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Percent change in Total Cholesterol (TC) over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Absolute change in TC over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Percent change in Triglycerides (TGs) over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Absolute change in TGs over time
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Presence of anti-evinacumab antibodies
Time Frame: Up to 192 weeks
|
Up to 192 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 13, 2018
Primary Completion (Actual)
April 13, 2023
Study Completion (Actual)
April 13, 2023
Study Registration Dates
First Submitted
January 8, 2018
First Submitted That Met QC Criteria
January 17, 2018
First Posted (Actual)
January 24, 2018
Study Record Updates
Last Update Posted (Actual)
May 3, 2023
Last Update Submitted That Met QC Criteria
May 1, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R1500-CL-1719
- 2017-003170-13 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Homozygous Familial Hypercholesterolemia
-
Novartis PharmaceuticalsActive, not recruitingFamilial Hypercholesterolemia - HomozygousGreece, Lebanon, Turkey, France, Canada, Malaysia, Netherlands, United States
-
Novartis PharmaceuticalsRecruitingHeterozygous or Homozygous Familial HypercholesterolemiaNetherlands, Israel, Hungary, Italy, Germany, Spain, France, Norway, South Africa, Turkey, United Kingdom, Canada, Switzerland, Brazil, Lebanon, Slovenia, United States, Russian Federation, Taiwan
-
REGENXBIO Inc.National Heart, Lung, and Blood Institute (NHLBI)TerminatedHomozygous Familial Hypercholesterolemia (HoFH)United States, Canada, Italy, Netherlands
-
Institut Investigacio Sanitaria Pere VirgiliRecruitingFamilial Hypercholesterolemia | Familial Hypercholesterolemia - Homozygous | Familial Hypercholesterolemia - HeterozygousSpain
-
Novartis PharmaceuticalsCompletedElevated Cholesterol | Homozygous Familial Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia | ASCVDUnited States, Canada, Czechia, Denmark, Germany, Hungary, Netherlands, Poland, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingHomozygous Familial HypercholesterolemiaChina
-
Beijing Suncadia Pharmaceuticals Co., LtdNot yet recruitingHomozygous Familial Hypercholesterolemia
-
Arrowhead PharmaceuticalsActive, not recruitingHomozygous Familial HypercholesterolemiaAustralia, Canada, United States, South Africa
-
AkesoAD Pharmaceuticals Co., Ltd.CompletedHomozygous Familial HypercholesterolemiaChina
Clinical Trials on evinacumab
-
Regeneron PharmaceuticalsCompletedSevere Hypertriglyceridemia (sHTG)United States, Canada, Italy, United Kingdom
-
Regeneron PharmaceuticalsCompletedHomozygous Familial HypercholesterolemiaUnited States, Australia, Austria, Netherlands, Taiwan, Ukraine
-
Regeneron PharmaceuticalsCompletedHomozygous Familial HypercholesterolemiaUnited States, Netherlands, Australia, Austria, Canada, France, Greece, Italy, Japan, South Africa, Ukraine
-
Regeneron PharmaceuticalsCompletedHealthy VolunteersUnited States
-
Daniel GaudetUltragenyx Pharmaceutical IncActive, not recruitingSafety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaCanada
-
Regeneron PharmaceuticalsTerminatedHypertriglyceridemiaUnited States, Germany, Netherlands, Canada
-
Regeneron PharmaceuticalsCompletedHypercholesterolemiaUnited States, Spain, Australia, Netherlands, Japan, Jordan, Denmark, Israel, Sweden, South Africa, Canada, Austria, Czechia, France, Italy, New Zealand, Norway, Poland, Russian Federation, United Kingdom